a_dose_of_drug_smallbanner_R2

Blog News - A Dose of Drug Development is a web publication produced by Integrium. The blog post content included conveys subjects of discussion and practice in the drug development process along with real-time Integrium activity. Readers interested in following are welcome to comment and interact on the Integrium website blog space.


Integrium, LLC Executives to Attend 37th Annual J.P. Morgan Healthcare Conference San Francisco, CA

By: Kevin Cho

Tustin, CA – Integrium, LLC Executives will be in San Francisco during the 37th Annual J.P. Morgan Healthcare Conference held in Westin St. Francis Hotel during January 7th through 10th. J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

Looking to meet with various types of organizations, Integrium typically engages in collaboration with startups and investors to discuss new business ventures and ways to work in partnerships. Attendees are encouraged to connect with Integrium for a brief introduction meeting during the conference and can request meeting time-slots by contacting Mike Loftus, Executive Director of Business Development to schedule: Mike.Loftus@integrium.com.


Integrium, LLC Executives to Attend LD Micro 11th Annual Event Bel-Air, CA

By: Kevin Cho

Tustin, CA – Integrium, LLC Executives will be in Los Angeles area during the LD Micro 11th Annual Event held in Luxe Sunset Boulevard Hotel on December 4th through 6th. This event is one of the largest and most influential independent micro-cap conferences bringing together opportunities for private meetings spread amongst over 250 companies.

Looking to meet with various types of organizations, Integrium typically engages in collaboration with startups and investors to discuss new business ventures and ways to work in partnerships. Attendees are encouraged to connect with Integrium for a brief introduction meeting during the conference and can request meeting time-slots by contacting Mike Loftus, Executive Director of Business Development to schedule: Mike.Loftus@integrium.com.


Integrium, LLC Executives to Attend Microbiome R&D and Business Collaboration Forum San Diego, CA

By: Kevin Cho

Tustin, CA – Integrium, LLC Executives will be in San Diego during the Microbiome R&D and Business Collaboration Forum on October 29th and 30th at Paradise Point Resort & Spa, San Diego, CA. The Microbiome Conference will highlight the most attractive companies and thought leaders in the space encompassing educational content and the trajectory of the interesting industry.

Looking to meet with various types of organizations, Integrium typically engages in collaboration with startups and investors to discuss new business ventures and ways to work in partnerships. Attendees are encouraged to connect with Integrium for a brief introduction meeting during the conference and can request meeting time-slots by contacting Mike Loftus, Executive Director of Business Development to schedule: Mike.Loftus@integrium.com.


Integrium, LLC Executives to Attend Ladenburg Thalmann Healthcare Conference, New York

By: Kevin Cho

Tustin, CA – Integrium, LLC Executives will be in New York during the Ladenburg Thalmann Healthcare Conference on October 2nd at the Sofitel New York. The Ladenburg Thalmann Healthcare Conference will feature presentations from CEOs and other thought leaders of an extensive range of life sciences companies across the biopharmaceutical and medical technology sectors and will include one-on-one meetings with investors.

Looking to meet with various types of organizations, Integrium typically engages in collaboration with startups and investors to discuss new business ventures and ways to work in partnerships. Attendees are encouraged to connect with Integrium for a brief introduction meeting during the conference and can request meeting time-slots by contacting Mike Loftus, Executive Director of Business Development to schedule: Mike.Loftus@integrium.com.


Integrium, LLC Executives to Attend Microcap Conference, New York

By: Kevin Cho

Tustin, CA – Integrium, LLC Executives will be in New York during the Microcap Conference on October 1st and 2nd at The Essex House overlooking Central Park. The MicroCap Conference will highlight the most attractive companies across various sectors, including many of the thought leaders in the biotechnology industry.

Looking to meet with various types of organizations, Integrium typically engages in collaboration with startups and investors to discuss new business ventures and ways to work in partnerships. Attendees are encouraged to connect with Integrium for a brief introduction meeting during the conference and can request meeting time-slots by contacting Mike Loftus, Executive Director of Business Development to schedule: Mike.Loftus@integrium.com.


Despite market volatility, 2018 has been on an astounding year for the biotech companies.

By: Kevin Cho

Despite market volatility, 2018 has been on an astounding year for the biotech companies. The landscape for initial public offerings (IPOs) has caught the attention of many. Particularly in Massachusetts, which has record 13 IPOs since the beginning of the year, raising a combined $1.3 billion. This in comparison to 2014 exceeds Massachusetts’ biotechs raising $1.2 BIL and the year is yet to be over.

Another exciting sector of biotech is the growth of digital health startups and the fields of incorporating artificial intelligence (A.I.) to its technology. As many have expected the epidemic of A.I. to cross over to biotech, it is likely that this will be a huge part of the industry in the near future. How Integrium as a company plays a role in advanced technology such as these is that Integrium has the advantage of having 20 years of experience with variety of therapies within its portfolio. Since A.I. is reliant on data, Integrium can provide this in volumes to increase accuracy and precision of the field of interest.

With the recent boom of biotech IPOs, one may argue that there have been a huge collective raise, but the number of companies is less than its previous year. Though 2017 may have had more IPOs in 9 months of the year, but the capital raise is considerably different. As stated by Forbes, venture capitalists invested about $10.6 billion into healthcare within the first half of 2018. Though the number of companies may be less, there have been a significant increase in investments in the biotech sector.

Alongside this enthusiasm in the biotech market, Integrium strives to collaborate and assist alongside some of the key players to bring their innovations to the market. As all signs are pointing to the continued growth in biotech market, Integrium will grow in parallel with this market growth.

Check out our new website!
www.integrium.com

To learn more about Integrium, contact:
Kevin Cho
Business Development Analyst
kevin.cho@integrium.com
714-591-0267